1-20 of 22
Yan Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting PDHK1 by DCA to Restore NK Cell Function in Hepatocellular Carcinoma

Xinyi Yang, Yuanyuan Liu, Peng Wang, Min Li, Tong Xiang, Songzuo Xie, Minxing Li, Yan Wang, Desheng Weng, Jingjing Zhao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther OF1–OF12.
https://doi.org/10.1158/1535-7163.MCT-24-0222
Published: 05 September 2024
View article titled, Targeting PDHK1 by DCA to Restore NK Cell Function in Hepatocellular Carcinoma
Open the PDF for Targeting PDHK1 by DCA to Restore NK Cell Function in Hepatocellular Carcinoma in another window
Includes: Supplementary data
Journal Articles

Abstract B201: A phase 1 dose-finding study of X4P-001 (an oral CXCR4 inhibitor) and axitinib in patients with advanced renal cell carcinoma (RCC)

Michael Atkins, Richard Joseph, Thai Ho, Ulka Vaishampayan, Sarah Ali, Marc Matrana, Robert Alter, Jeff Edenfield, Yan Wang, Sarah Blanchette, Lu Gan, David McDermott
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (1_Supplement): B201.
https://doi.org/10.1158/1535-7163.TARG-17-B201
Published: 01 January 2018
View article titled, Abstract B201: A phase 1 dose-finding study of X4P-001 (an oral CXCR4 inhibitor) and axitinib in patients with advanced renal cell carcinoma (RCC)
Journal Articles

Inhibition of HSP90 by AUY922 Preferentially Kills Mutant KRAS Colon Cancer Cells by Activating Bim through ER Stress

Chun Yan Wang, Su Tang Guo, Jia Yu Wang, Fen Liu, Yuan Yuan Zhang, Hamed Yari, Xu Guang Yan, Lei Jin, Xu Dong Zhang, Chen Chen Jiang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (3): 448–459.
https://doi.org/10.1158/1535-7163.MCT-15-0778
Published: 06 March 2016
View article titled, Inhibition of HSP90 by AUY922 Preferentially Kills Mutant <em>KRAS</em> Colon Cancer Cells by Activating Bim through ER Stress
Open the PDF for Inhibition of HSP90 by AUY922 Preferentially Kills Mutant <em>KRAS</em> Colon Cancer Cells by Activating Bim through ER Stress in another window
Includes: Supplementary data
Journal Articles

Optimization of RGD-Containing Cyclic Peptides against αvβ3 Integrin

Yan Wang, Wenwu Xiao, Yonghong Zhang, Leah Meza, Harry Tseng, Yoshikazu Takada, James B. Ames, Kit S. Lam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (2): 232–240.
https://doi.org/10.1158/1535-7163.MCT-15-0544
Published: 07 February 2016
View article titled, Optimization of RGD-Containing Cyclic Peptides against αvβ3 Integrin
Open the PDF for Optimization of RGD-Containing Cyclic Peptides against αvβ3 Integrin in another window
Includes: Supplementary data
Journal Articles

Abstract A191: FAK/PYK2 inhibitors defactinib and VS-4718 enhance immune checkpoint inhibitor efficacy

Jennifer E. Ring, Yajuan Li, Irina M. Shapiro, Yan Wang, David T. Weaver, Jonathan A. Pachter
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A191.
https://doi.org/10.1158/1535-7163.TARG-15-A191
Published: 01 December 2015
View article titled, Abstract A191: FAK/PYK2 inhibitors defactinib and VS-4718 enhance immune checkpoint inhibitor efficacy
Journal Articles

Abstract A1: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors

Jian-Ming Xu, Lin Sheng, Yan Wang, Yu-Ling Chen, Ru Jia, Jian Wang, Ke Li, Yang Sai, Jing Li, Chuan Qi, Ye Hua, Wei-Guo Su
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A1.
https://doi.org/10.1158/1535-7163.TARG-15-A1
Published: 01 December 2015
View article titled, Abstract A1: First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors
Journal Articles

Abstract B169: A mouse avatar tumor maintenance study identified a subset of SCLC patient-derived tumor xenograft models sensitive to the PARP inhibitor niraparib

Keith Mikule, Yan Wang, Yonhong Xiao, Jill Rocono, Thomas Broudy, Keith Wilcoxen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B169.
https://doi.org/10.1158/1535-7163.TARG-15-B169
Published: 01 December 2015
View article titled, Abstract B169: A mouse avatar tumor maintenance study identified a subset of SCLC patient-derived tumor xenograft models sensitive to the PARP inhibitor niraparib
Journal Articles

Abstract C29: FAK inhibition targets cancer stem cells

Vihren Kolev, Yan Wang, Kam Sprott, Irina Shapiro, Jennifer Ring, Jonathan Pachter, David Weaver
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C29.
https://doi.org/10.1158/1535-7163.TARG-15-C29
Published: 01 December 2015
View article titled, Abstract C29: FAK inhibition targets cancer stem cells
Journal Articles

Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus

Hung Huynh, Huai-Xiang Hao, Stephen L. Chan, David Chen, Richard Ong, Khee Chee Soo, Panisa Pochanard, David Yang, David Ruddy, Manway Liu, Adnan Derti, Marissa N. Balak, Michael R. Palmer, Yan Wang, Benjamin H. Lee, Dalila Sellami, Andrew X. Zhu, Robert Schlegel, Alan Huang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (5): 1224–1235.
https://doi.org/10.1158/1535-7163.MCT-14-0768
Published: 05 May 2015
View article titled, Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus
Open the PDF for Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus in another window
Includes: Supplementary data
Journal Articles

Abstract C287: Efficacy and safety of the TH-302, gemcitabine, and nab-paclitaxel combination in xenograft models of pancreatic cancer.

Jessica D. Sun, Qian Liu, Dharmendra Ahluwalia, Wenwu Li, Yan Wang, Ayesha S. Ruprell, Charles P. Hart
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C287.
https://doi.org/10.1158/1535-7163.TARG-13-C287
Published: 01 November 2013
View article titled, Abstract C287: Efficacy and safety of the TH-302, gemcitabine, and nab-paclitaxel combination in xenograft models of pancreatic cancer.
Journal Articles

Abstract C198: Phase I study on safety and pharmacokinetics of sulfatinib, a selective VEGFR/FGFR dual inhibitor, in Chinese patients with advanced solid tumors.

Jianming Xu, Yan Wang, Chenyang Ye, Lin Shen, Cheng Huang, Li Yang, Yang Sai, Hua Mu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): C198.
https://doi.org/10.1158/1535-7163.TARG-11-C198
Published: 12 November 2011
View article titled, Abstract C198: Phase I study on safety and pharmacokinetics of sulfatinib, a selective VEGFR/FGFR dual inhibitor, in Chinese patients with advanced solid tumors.
Journal Articles

Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase

Chun-Te Chen, Hirohito Yamaguchi, Hong-Jen Lee, Yi Du, Heng-Huan Lee, Weiya Xia, Wen-Hsuan Yu, Jennifer L. Hsu, Chia-Jui Yen, Hui-Lung Sun, Yan Wang, Edward T.H. Yeh, Gabriel N. Hortobagyi, Mien-Chie Hung
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (8): 1327–1336.
https://doi.org/10.1158/1535-7163.MCT-10-1117
Published: 08 August 2011
View article titled, Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase
Open the PDF for Dual Targeting of Tumor Angiogenesis and Chemotherapy by Endostatin–Cytosine Deaminase–Uracil Phosphoribosyltransferase in another window
Includes: Supplementary data
Journal Articles

p53R2 Inhibits the Proliferation of Human Cancer Cells in Association with Cell-Cycle Arrest

Keqiang Zhang, Jun Wu, Xiwei Wu, Xiaochen Wang, Yan Wang, Ning Zhou, Mei-ling Kuo, Xiyong Liu, Bingsen Zhou, Lufen Chang, David Ann, Yun Yen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (2): 269–278.
https://doi.org/10.1158/1535-7163.MCT-10-0728
Published: 08 February 2011
View article titled, p53R2 Inhibits the Proliferation of Human Cancer Cells in Association with Cell-Cycle Arrest
Open the PDF for p53R2 Inhibits the Proliferation of Human Cancer Cells in Association with Cell-Cycle Arrest in another window
Includes: Supplementary data
Journal Articles

The Use of One-Bead One-Compound Combinatorial Library Technology to Discover High-Affinity αvβ3 Integrin and Cancer Targeting Arginine-Glycine-Aspartic Acid Ligands with a Built-in Handle

Wenwu Xiao, Yan Wang, Edmond Y. Lau, Juntao Luo, Nianhuan Yao, Changying Shi, Leah Meza, Harry Tseng, Yoshiko Maeda, Pappanaicken Kumaresan, Ruiwu Liu, Felice C. Lightstone, Yoshikazu Takada, Kit S. Lam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (10): 2714–2723.
https://doi.org/10.1158/1535-7163.MCT-10-0308
Published: 10 October 2010
View article titled, The Use of One-Bead One-Compound Combinatorial Library Technology to Discover High-Affinity αvβ3 Integrin and Cancer Targeting Arginine-Glycine-Aspartic Acid Ligands with a Built-in Handle
Open the PDF for The Use of One-Bead One-Compound Combinatorial Library Technology to Discover High-Affinity αvβ3 Integrin and Cancer Targeting Arginine-Glycine-Aspartic Acid Ligands with a Built-in Handle in another window
Includes: Supplementary data
Journal Articles

A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts

Yaolin Wang, Philip Lipari, Xiaoying Wang, Judith Hailey, Lianzhu Liang, Robert Ramos, Ming Liu, Jonathan A. Pachter, W. Robert Bishop, Yan Wang
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (2): 410–418.
https://doi.org/10.1158/1535-7163.MCT-09-0555
Published: 09 February 2010
View article titled, A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts
Open the PDF for A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts in another window
Includes: Supplementary data
Journal Articles

Abstract A49: FDG‐PET as an imaging biomarker for the response of xenograft tumors to IGF‐1R inhibition

Yan Wang, Yaolin Wang, Xiaoying Wang, Judith Hailey, Philip Lipari, Cindy Seidel‐Dugan, Steve Larsson
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A49.
https://doi.org/10.1158/1535-7163.TARG-09-A49
Published: 10 December 2009
View article titled, Abstract A49: FDG‐PET as an imaging biomarker for the response of xenograft tumors to IGF‐1R inhibition
Journal Articles

KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo

Christian A. Hassig, Kent T. Symons, Xin Guo, Phan-Manh Nguyen, Tami Annable, Paul L. Wash, Joseph E. Payne, David A. Jenkins, Céline Bonnefous, Carol Trotter, Yan Wang, John V. Anzola, Elena L. Milkova, Timothy Z. Hoffman, Sara J. Dozier, Brandon M. Wiley, Alan Saven, James W. Malecha, Robert L. Davis, Jerry Muhammad, Andrew K. Shiau, Stewart A. Noble, Tadimeti S. Rao, Nicholas D. Smith, Jeffrey H. Hager
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (5): 1054–1065.
https://doi.org/10.1158/1535-7163.MCT-07-2347
Published: 15 May 2008
View article titled, KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity <em>in vitro</em> and <em>in vivo</em>
Open the PDF for KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity <em>in vitro</em> and <em>in vivo</em> in another window
Includes: Supplementary data
Journal Articles

Identification of cancer specific high affinity targeting ligands by screening One-bead-one-compound and small molecule combinatorial libraries

Pappanaicken Kumaresan, Vaishali Ahir, Ruiwu Liu, Yan Wang, Anirban Maitra, kit Lam
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): A220.
Published: 01 November 2007
View article titled, Identification of cancer specific high affinity targeting ligands by screening One-bead-one-compound and small molecule combinatorial libraries
Journal Articles

From OBOC combinatorial chemistry to glioblastoma targeting

Kit Lam, Wenwu Xiao, Nianhuan Yao, Ruiwu Liu, Olulanu Aina, Li Peng, Mirela Andrei, Yan Wang, Sally DeNardo, Arut Natarajan, Julie Sutcliffe, Simon Cherry, Yoshi Takada, Mark Kurth, Rick Carpenter, Michael Kent, Erik Wisner, Allison Zwingenberger
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): C121.
Published: 01 November 2007
View article titled, From OBOC combinatorial chemistry to glioblastoma targeting
Journal Articles

Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody

Yan Wang, Judith Hailey, Denise Williams, Yaolin Wang, Philip Lipari, Michael Malkowski, Xiaoying Wang, Lei Xie, Guanghua Li, Deba Saha, Wai Lam W. Ling, Susan Cannon-Carlson, Robert Greenberg, Robert A. Ramos, Robert Shields, Leonard Presta, Peter Brams, W. Robert Bishop, Jonathan A. Pachter
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2005) 4 (8): 1214–1221.
https://doi.org/10.1158/1535-7163.MCT-05-0048
Published: 10 August 2005
View article titled, Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody
Open the PDF for Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti–IGF-IR antibody in another window